関連する実験動画
Updated: Jul 15, 2026

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
組織プラズミノゲンアクティベーター/P-セレクチン融合タンパク質は,効果的な血栓駆除剤です
K Fujise1, B M Revelle, L Stacy
1Department of Internal Medicine, University of Texas-Houston Health Science Center 77030, USA. kfujise@heart.med.uth.tmc.edu
Circulation
|February 4, 1997
まとめ
エンジニアリングされた組織プラズミノゲン活性化剤 (TPA) /P-セレクチン融合タンパク質は,単独のTPAに類似した効果的な血栓駆除活性を示しています. これらの新しいキメリックタンパク質は,血栓への標的の投与の可能性を示し,治療戦略を強化しています.
科学分野:
- バイオケミストリー バイオケミストリー
- 分子生物学は分子生物学である.
- トロンボシス研究研究
背景:
- P-セレクチンは,活性化された内皮細胞と血小板に発現します.
- TPA/P-セレクチン融合タンパク質が,TPAをトロンビアに標的とすることができると仮定した.
- P-セレクチン.インに白血球結合の競争抑制の可能性を調査した.
研究 の 目的:
- 血栓解消療法のためのTPA/P-セレクチン融合タンパク質の開発と評価.
- これらのキメリックタンパク質の標的型投与と治療効果を評価する.
- 融合タンパク質がネイティブTPAに優れているかどうかを判断する.
主な方法:
- バキュロウイルスベクトルを使用した全長TPA阻害剤-1-耐性TPA (TPAIR) と融合構造 (P280IR,P121IR) を表現した.
- 金属イオンクロマトグラフィによる浄化された再結合タンパク質.
- 評価された血栓解消活性 in vitro (凝固溶解検査) と in vivo (ラット中枢動脈モデル).
主要な成果:
- TPAIR,P280IR,P121IRは,in vitroの凝固溶解の効果が類似していた.
- イン・ビボ試験では,試験されたすべての分子のサイクルフローの変動の有意で比較可能な減少が示されました.
- 治療を受けた動物では,有意な出血合併症は観察されなかった.
結論:
- 化学タンパク質P280IRとP121IRは,TPAIRに匹敵する,in vitroおよびin vivoの凝固溶解活動を有しています.
- これらの融合タンパク質は,P-セレクチンリガンドと結合し,標的型血栓解離の可能性を示唆する.
- より大きな動物モデルでのさらなる研究は,臨床的治療の可能性を探求するために正当化されています.
関連する概念動画
Selectins
Cell adhesion is an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain, which...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

